Publications

Selected publications:

A complete list of publications can be found here.

Chen ML, Huang X, Wang H, Hegner C, Liu Y, Shang J, Eliason A, Diao H, Park H, Frey B, Wang G, Mosure SA, Solt LA, Kojetin DJ, Rodrigues-Palacios A, Schady DA, Weaver CT, Pipkin ME, Moore DD, Sundrud MS. CAR directs T cell adaptation to bile acids in the small intestine.  Nature. 2021 May; 593(7857):147-151.  PMID: 33828301

Mosure SA,  Strutzenberg TS, Shang J, Munoz-Tello P, Solt LA, Griffin PR, Kojetin DJ. Structural basis for heme-dependent NCoR binding to the transcriptional repressor REV-ERBb.  Sci Adv. 2021 Jan 21;7(5):eabc6479.  PMID: 33571111.

Mosure SA,  Solt LA. Uncovering New Challenges in Targeting Glycolysis to Treat Th17 Cell-Mediated Autoimmunity.  Immunometabolism. 2021;3(1):e210006.   PMID: 33614166.

Wang R, Campbell S, Amir M, Mosure SA, Eliason A, Sundrud MS, Kamenecka TM, Solt LA. Genetic and pharmacological inhibition of the nuclear receptor RORa regulates TH17 driven inflammatory disorders.  Nat Commun. 2021 Jan 4;12(1):76.  PMID: 33397953.

Amir M, Campbell S, Kamenecka TM, Solt LA. Pharmacological modulation and genetic deletion of REV-ERBa and REV-ERBb regulates dendritic cell development.  Biochem Biophys Res Commun. 2020 May 18:S0006-291X(20)30913-X.  PMID: 32439175.

Shang J, Mosure SA, Zheng J, Brust R, Bass J, Nichols A, Solt LA, Griffin PR, Kojetin DJ.  A molecular switch regulating transcriptional repression and activation of PPARg.  Nat Commun. 2020 Feb 19; 11 (1): 956.  PMID: 32075969.

Haspel JA, Anafi R, Brown MK, Cermakian N, Depner C, Desplats P, Gelman AE, Haack M, Jelic S, Kim BS, Laposky AD, Lee YC, Mongodin E, Prather AA, Prendergast BJ, Reardon C, Shaw AC, Sengupta S, Szentirmai É, Thakkar M, Walker WE, Solt LA.  Perfect timing: circadian rhythms, sleep, and immunity – an NIH workshop summary.  JCI Insight. 2020 Jan 16; 5 (1): Review. PMID: 31941836.

Galmozzi A, Kok BP, Kim AS, Montenegro-Burke JR, Lee JY, Spreafico R, Mosure S, Albert V, Cintron-Colon R, Godio C, Webb WR, Conti B, Solt LA, Kojetin D, Parker CG, Peluso JJ, Pru JK, Siuzdak G, Cravatt BF and Saez E. PGRMC2 is an Intracellular Heme Chaperone Critical for Adipocyte Function.  Nature. 2019 Nov 20; 575 (7783): [Epub ahead of print]. PMID: 31748741.

Wang Q, Robinette ML, Billon C, Collins PL, Bando JK, Fachi JL, Secca C, Porter SI, Saini A, Gilfillan S, Solt LA, Musiek ES, Oltz EM, Burris TP, and Colonna M. Circadian rhythm-dependent and circadian rhythm-independent impacts of the molecular clock on type 3 innate lymphoid cells.  Sci Immunol. 2019 Oct 4;4(40).  PMID: 31586012.

Chang C, Loo CS, Zhao X, Solt LA, Liang Y, Bapat SP, Cho H, Kamenecka TM, Leblanc M, Atkins AR, Yu RT, Downes M, Burris TP, Evans RM, and Zheng Y. The nuclear receptor REV-ERBα modulates Th17 cell-mediated autoimmune disease.  Proc Natl Acad Sci. 2019 Sep 10;116(37):18528-18536. PMID: 31455731.

Doebelin C, He Y, Campbell S, Nuhant P, Kumar N, Koenig M, Garcia-Ordonez R, Chang MR, Roush WR, Lin L, Kahn S, Cameron MD, Griffin PR, Solt LA, and Kamenecka TM.  Discovery and optimization of a series of sulfonamide inverse agonists for the retinoic acid receptor-related receptor-a. Med Chem. 2019 Feb 22;[Epub ahead of print]. PMID: 30799793.

Amir M, Chaudhari S, Wang R, Campbell S, Mosure SA, Chopp LB, Lu Q, Shang J, Pelletier OB, He Y, Doebelin C, Cameron MD, Kojetin DJ, Kamenecka TM, Solt LA. REV-ERBa Regulates TH17 Cell Development and Autoimmunity. Cell Rep. 2018 Dec 26;25(13):3733-3749. PMID:30590045.

Doebelin C, Patouret R, Garcia-Ordonez RD, Chang MR, Dharmarajan V, Novick S, Ciesla A, Campbell S, Solt LA, Griffin PR, Kamenecka TM.   Identification of potent RORb modulators: Scaffold variation. Bioorg Med Chem Lett.  2018 Aug 16; [Epub ahead of print]. PMID:30143422.

Zhao J, Zhang L, Mu X, Doebelin C, Nguyen W, Wallace C, Reay DP, McGowan S, Corbo L, Clemens PR, Wilson GM, Watkins SC, Solt LA, Cameron MD, Huard J, Niedernhofer LJ, Kamenecka TM, and Robbins PD. Development of Novel NEMO-Binding Domain mimetics for inhibiting IKK/NF-κB activation.  PLoS Biol. 2018 Jun 11; 16(6):e2004663. PMID: 29889904.

Amador A, Campbell S, Kazantzis M, Lan G, Burris TP, and Solt LA. Distinct roles for REV-ERBα and REV-ERBβ in oxidative capacity and mitochondrial biogenesis in skeletal muscle. PLoS One. 2018 May 3; 13(5) e0196787. PMID: 29723273.

Amador A, Kamenecka TM, Solt LA, and Burris TP. REV-ERBb is required to maintain normal wakefulness and the wake-inducing effect of dual REV-ERB agonist SR9009. Biochem Pharmacol. 2018 Jan 22; 150:1-8. PMID:29355503.

Sun Y, Liu CH, Wang Z, Meng SS, Burnim SB, SanGiovanni JP, Kamenecka TM, Solt LA, and Chen J.   RORa modulates semaphoring 3E transcription and neurovascular interaction in pathological retinal angiogenesis.  FASEB J.  2017 Jun 23 [Epub ahead of print].  PMID: 28646017.

Amador A, Huitron-Resendiz S, Roberts AJ, Kamenecka TM, Solt LA, and Burris TP. Pharmacological targeting the REV-ERBs in sleep/wake regulation. PLoS One. 2016 Sep 7;11(9)e0162452.  PMID: 27603791.

de Vera IM, Giri PK, Munoz-Tello P, Brust R, Fuhrmann J, Matta-Camacho E, Shang J, Campbell S, Wilson HD, Granados J, Gardner WJ Jr, Creamer TP, Solt LA,  and Kojetin DJ.  Identification of a Binding Site for Unsaturated Fatty Acids in the Orphan Nuclear Receptor Nurr1. ACS Chem Biol. 2016 Jul 15:11(7):1795-9. PMID: 27128111.

Amador A, Wang Y, Banerjee S, Kamenecka TM, Solt LA, Burris TP. Pharmacological and Genetic Modulation of REV-ERB Activity and Expression Affects Orexigenic Gene Expression.  PLoS One. 2016 Mar 10;11(3):e0151014. doi: 10.1371/journal.pone.0151014. eCollection 2016. PMID: 26963516.

Wang R, Solt LAMetabolism of Murine TH17 cells: impact on cell fate and function. Eur J Immunol.  2016 Apr;46(4):807-16.  PMID: 26893133.

Sun Y, Liu CH, SanGiovanni JP, Evans LP, Tian KT, Zhang B, Stahl A, Pu WT, Kamenecka TM, Solt LA, and Chen J.   Nuclear Receptor RORa regulates pathological angiogenesis by modulating SOCS3-dependent inflammation. Proc Natl Acad Sci U S A. Proc Natl Acad Sci U S A. 2015 Aug 18;112(33):10401-6. PMID: 26243880

Flaveny CA, Griffett K, El-Gendy BE, Kazantzis M, Sengupta M, Amelio AL, Chatterjee A, Walker J, Solt LA, Kamenecka TM, and Burris TP.   Broad Anti-Tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and LipogenesisCancer Cell. 2015 Jul 13;28(1):42-56.  PMID: 26120082

Solt LA, Burris TP.  Th17 cells in Type 1 diabetes: a future perspectiveDiabetes Manag (Lond). 2015 Jul;5(4):247-250. PMID: 27708719

Sitaula S, Billon C, Kamenecka TM, Solt LA, and Burris TP.  Suppression of Atherosclerosis by Synthetic REV-ERB AgonistBiochem Biophys Res Commun.  2015 Mar 20. pii: S0006-291X(15)00516-1. [Epub ahead of print] PMID: 25800870.

Solt LA, Banerjee S, Campbell S, Kamenecka TM, and Burris TP.  ROR Inverse Agonist Suppresses Insulitis and Prevents Hyperglycemia in a Mouse Model of Type 1 DiabetesEndocrinology. 2015 Mar;156(3):869-81.PMID: 25560829.

Highlighted in: Jax Mice eNews (The Jackson Laboratories eNews & Events), Feb. 4, 2015; Medical Express: New compound prevents onset of type 1 diabetes in animal models. March 17, 2015.

Banerjee S, Wang Y, Solt LA, Griffett K, Kazantzis M, Amador A, El-Gendy BM, Huitron-Resendiz S, Roberts AJ, Shin Y, Kamenecka TM, and Burris TP.   Pharmacological targeting of the mammalian clock regulates sleep architecture and emotional behaviourNat Commun.  2014 Dec 23;5:5759. doi: 10.1038/ncomms6759.  PMID: 25536025.

Matta-Camacho E, Banerjee S, Hughes TS, Solt LA, Burris TP, and Kojetin DJ.  Structure of REV-ERBb Ligand-Binding Domain Bound to a Porphyrin AntagonistJ Biol Chem.  2014 May 28; pii: jbc.M113.545111. [Epub ahead of print].  PMID: 24872411

Gray AM, Remouchamps C, McCorkell KA, Solt LA, Dejardin E, Orange JS, May MJ.  Noncanonical NF-kB Signaling Is Limited by Classical NF-kB ActivitySci. Signal.  2014 Feb 4; 311(7): ra13.  PMID: 24497610

Woldt E, Sebti Y, Solt LA, Duhem C, Lancel S, Eeckhoute J, Hesselink MK, Paquet C, Delhaye S, Shin Y, Kamenecka TM, Schaart G, Lefebvre P, Nevière R, Burris TP, Schrauwen P, Staels B, Duez H.  Rev-erba modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagyNat Med.  2013 Jul 14. doi: 10.1038/nm.3213. [Epub ahead of print] PMID: 23852339. PMCID: PMC3737409

Burris TP, Solt LA, Wang Y, Crumbley C, Banerjee S, Griffett K, Lundasen T, Hughes T, Kojetin DJ.  Nuclear Receptors and Their Selective Pharmacological Modulators. Pharmacol Rev.  2013 Mar 1;65(2):710-778. PMID: 23457206.

Griffett K, Solt LA, El-Gendy BE, Kamenecka TM, and Burris TP.  A Liver Selective Inverse Agonist that Suppresses Hepatic Steatosis. ACS Chem Biol. 2012 Dec 13. [Epub ahead of print]. PMID: 23237488.

Solt LA, Kamenecka TM, and Burris TP.  LXR-Mediated Inhibition of CD4+ T Helper Cells. PLoS One. 2012;7(9):e46615. doi: 10.1371/journal.pone.0046615. Epub 2012 Sep 28. PMID: 23029557

Solt LA and Burris TP.  Action of RORs and Their Ligands in (patho) Physiology. Trends Endocrinol Metab. 2012 Jul 10. [Epub ahead of print]. PMID: 22789990

Solt LA, Kumar N, He Y, Kamenecka TM, Griffin PR and Burris, TP. Identification of a Selective RORg Ligand that Suppresses TH17 cells and Stimulates T Regulatory CellsACS Chem Biol. 2012 Jul 9. [Epub ahead of print].  PMID:  22769242. PMCID: PMC3448878.

Solt LA, Wang Y, Banerjee S, Hughes T, Kojetin DJ, Lundasen T, Shin Y, Liu J, Cameron MD, Noel R, Yoo SH, Takahashi JS, Butler AA, Kamenecka TM and  Burris TP.  Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists.  Nature. 2012 Mar 29; 485 (7396): 62-8.  PMID: 22460951. PMCID: PMC3343186.

News & Views: Drug discovery: Time in a Bottle. Nature 2012. 485:45-46.  Preview: REV-ERBs: More Than the Sum of the Individual Parts. Cell Metabolism 2012 15:791-793; Pumping up the Metabolic REV-ERB.  Nature SciBX 2012 5:6-7; Research Highlight: REV-ERB-erating Nuclear Receptor Functions in Circadian Metabolism and Physiology. Cell Research 2012 1-3. Scripps Research Scientists Synthetize Compounds that Dramatically Alter Circadian Rhythms. Drug Discovery News April 24, 2012; Clinical Implications of Basic Research: Obesity and Pharmacologic Control of the Body Clock. New England Journal of Medicine 2012 367:175-178. Faculty of 1000 “must read” paper. Highlighted in: NIDDK Recent Advances and Emerging Opportunities, Feb 2013, pp 33-35.

Kumar N, Lyda B, Chang MR, Lauer JL, Solt LA, Burris TP, Kamenecka TM and Griffin PR. Identification of SR2211: A Potent Synthetic RORγ-Selective Modulator. ACS Chem Biol. 2012 Apr 20;7(4):672-7. PMID: 22292739.  PMCID: PMC3331898.

Solt LA, Kojetin DJ and Burris TP. The REV-ERBs and RORs: molecular links between circadian rhythms and lipid homeostasis. Future Med Chem. 2011 Apr; 3 (5): 623-38. PMID: 21526899.  PMCID: PMC3134326.

Solt LA, Kumar N, Nuhant P, Wang Y, Lauer JL, Liu J, Istrate MA,               Kamenecka TM, Roush WR, Vidović D, Schürer SC, Xu J, Wagoner G, Drew PD, Griffin PR and Burris TP.  Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand.  Nature. 2011 Apr 28; 472 (7344): 491-4. PMID: 21499262.  PMCID:  PMC3148894.

News & Views: Immunology: A helping hand against autoimmunity. Nature 2011 472:421-422.  Cover Story: Immune dampening at the source. Nature SciBX 2011 4: 1-3. Research Highlights: Taking aim at ROR-gt. Nature Medicine 2011 17:556. Research Highlights: TH17 cell differentiation inhibitors. Nature Biotechnology 2011 29:410. Research Highlight: Autoimmune disease: Blocking the drivers. Nature Rev. Drug Discov. 2011 10, 413. Research Highlights: Autoimmunity: Targeting orphan receptors. Nature Chemical Biology 2011 7:406-407. Research Highlights: ROR blockers inhibit TH17 cellsNature Reviews Neurology 2011 7: 302.  Faculty of 1000 “exceptional” paper.

Kumar N, Kojetin DJ, Solt LA, Kumar KG, Nuhant P, Duckett DR, Cameron MD, Butler AA, Roush WR, Griffin PR and Burris TP.  Identification of SR3335 (ML-176): A Synthetic RORα Selective Inverse Agonist. ACS Chem Biol. 2011 Mar 18; 6 (3): 218-22. PMID: 21090593.  PMCID: PMC3076127.